Antipodes Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $40M | Sell |
122,804
-36,750
| -23% | -$12M | 1.24% | 26 |
|
|
2025
Q1 | $43.1M | Buy |
159,554
+25,795
| +19% | +$6.97M | 1.35% | 24 |
|
|
2024
Q4 | $31.5M | Sell |
133,759
-5,616
| -4% | -$1.32M | 1.09% | 29 |
|
|
2024
Q3 | $38.3M | Sell |
139,375
-99,121
| -42% | -$27.3M | 1.33% | 28 |
|
|
2024
Q2 | $58M | Buy |
238,496
+32,917
| +16% | +$8M | 2.11% | 23 |
|
|
2024
Q1 | $30.7M | Buy |
205,579
+16,438
| +9% | +$2.46M | 0.97% | 29 |
|
|
2023
Q4 | $36.2M | Buy |
189,141
+77,307
| +69% | +$14.8M | 1.13% | 28 |
|
|
2023
Q3 | $19.5M | Buy |
111,834
+111,778
| +199,604% | +$19.5M | 0.63% | 33 |
|
|
2023
Q2 | $10K | Sell |
56
-84
| -60% | -$15K | ﹤0.01% | 65 |
|
|
2023
Q1 | $28K | Buy |
140
+22
| +19% | +$4.4K | ﹤0.01% | 61 |
|
|
2022
Q4 | $28K | Buy |
+118
| New | +$28K | ﹤0.01% | 62 |
|